Table 2.

Chemotherapy details

	Cisplatin and fluorouracil: two cycles (n=451)	Epirubicin, cisplatin, and capecitabine: four cycles (n=446)
Cycles started
None*	2 (<1%)	2 (<1%)
One	14 (3%)	12 (3%)
Two (completed two-cycle regimen)	435 (96%)	32 (7%)
Three	NA	37 (8%)
Four (completed four-cycle regimen)	NA	363 (81%)
Total completed chemotherapy	435 (96%)	363 (81%)
Delays to cycles†
Yes	113 (25%)	148 (33%)
No	336 (75%)	296 (66%)
No chemotherapy received	2 (<1%)	2 (<1%)
Reduction in cisplatin dose‡
No	373 (83%)	378 (85%)
Yes	61 (14%)	53 (12%)
No cisplatin given	1 (<1%)	1 (<1%)
Less than two cycles given	16 (4%)	14 (3%)
Reduction in any dose‡
No	347 (77%)	245 (55%)
Yes	88 (20%)	187 (42%)
Less than two cycles given	16 (4%)	14 (3%)

Data are n (%). NA=not applicable.

^*All four patients who received no on-trial chemotherapy withdrew consent soon after randomisation.

^†A delay is defined as a cycle starting at least 25 days after the previous cycle, or at least 11 days after randomisation.

^‡A reduction is defined as the dose decreasing by more than 10% compared with cycle one. A cycle was said to have started if any drug was administered.